Alexey Dzasokhov

Alexey Dzasokhov

Auto-generated profile, based on publicly available information

Alexey Dzasokhov

Moscow Regional Oncological Dispensary

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in South Russian Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasokhov
A. S. Dzasokhov
AKA. A. Kostin
A. A. Kostin
VAV. L. Astashov
V. L. Astashov
МАМ. А. Андреева
М. А. Андреева
ATA. V. Turiev
A. V. Turiev
AUA. D. Uskov
A. D. Uskov
Purpose of the study. Dynamic assessment of the direct impact of pressurized intraperitoneal aerosol chemotherapy (PIPAC) on peritoneal carcinomatosis in ovarian cancer.Patients and methods. The study involved 164 people with visually detectable and morphologically verified ovarian cancer with peritoneal carcinomatosis of the peritoneum (IIIb-IIIc stages of ovarian cancer). All patients underwent combined treatment of ovarian cancer, which included primary cytoreduction and 6 courses of сhemotherapy according to the TC scheme. In the main group, the standard treatment was supplemented with 3 sessions of PIPAC. Statistical processing was carried out by analyzing the exact criterion of the Wilcoxon-Mann-Whitney sums, the distribution of patients in groups by age and peritoneal lesion was estimated. It was found that the distribution of the analyzed parameters was random. The distribution in the groups by stages of the disease was homogeneous, which is justified by the use of the Barnard criterion. The dynamics of the parameters of the study was evaluated by the methods of basic statistics. Used software packages: MedCals, Statistica.Results. The results obtained demonstrate a distinct positive dynamics in the group of patients receiving PIPAC in addition to standard treatment of newly diagnosed ovarian cancer: a significant decrease in the peritoneal cancer index, therapeutic pathomorphosis in peritoneal samples during treatment, reduction of ascites.Conclusion. The team of authors managed to establish that PIPAC simultaneously with standard combined treatment for newly diagnosed ovarian cancer with peritoneal carcinomatosis makes it possible to achieve a dynamic regression effect of peritoneal carcinomatosis of the peritoneum, morphological regression of carcinomatosis and complete resorption of ascites in the vast majority of treated patients. The revealed therapeutic effect was prolonged and persistent with an objective assessment 6 months after the end of treatment.

26 March 2023 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasokhov
A. S. Dzasokhov
AKA. A. Kostin
A. A. Kostin
VAV. L. Astashov
V. L. Astashov
ATA. V. Turiev
A. V. Turiev
AUA. D. Uskov
A. D. Uskov
The relevance of the problem of increasing the effectiveness of standard treatment of ovarian cancer is determined by the following characteristics of the disease: high one‑year mortality, high recurrence rate and unsatisfactory results of their treatment. Peritoneal carcinomatosis in ovarian cancer occurs in 65–70 % of cases. The standard modern approach to the treatment of ovarian cancer is a combination of surgical treatment and systemic intravenous chemotherapy. At the same time, more than 70 % of ovarian cancer cases are first diagnosed at stages III–IV. However, despite the successes in the field of surgery and drug treatment, the five‑year survival rate is no more than 24 % at the III and 4.6 % at the IV stage of the disease. One of the frontiers of ovarian cancer resistance to therapy is peritoneal carcinomatosis. Its resistance to therapy is due to the low bioavailability of cytostatics in metastases on the peritoneum to almost zero. In order to increase bioavailability, various forms of intra‑abdominal chemotherapy are used. The technique of pressurized intraperitoneal aerosol chemotherapy (PIPAC) has a number of advantages over other methods of intra‑abdominal antitumor treatment. These advantages include the uniform distribution of cytostatics over the peritoneum, the absence of penetration of cytostatics beyond the peritoneum, which allows PIPAC to be combined with systemic chemotherapy, low trauma and good tolerability of the procedure. PIPAC was implemented into clinical practice in 2011, and since then has been widely used in a number of foreign and domestic clinics. The conducted studies confirm the safety of the technique and its effectiveness against peritoneal carcinomatosis. The data of multicenter studies and the analysis of available literature data, as well as the successful own experience of PIPAC use create prerequisites for investigating the effectiveness of intra‑abdominal aerosol chemotherapy under pressure in relation to peritoneal carcinomatosis in ovarian cancer.

4 December 2024 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasochov
A. S. Dzasochov
AKA. A. Kostin
A. A. Kostin
VAV. L. Astashov
V. L. Astashov
MAM. A. Andreeva
M. A. Andreeva
ATA. B. Turiev
A. B. Turiev
НУН. Ю. Уразовский
Н. Ю. Уразовский
Клиническая эффективность внутрибрюшной аэрозольной химиотерапии под давлением при комбинированном лечении впервые выявленного рака яичников с перитонеальным канцероматозом и асцитом

26 March 2023 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasokhov
A. S. Dzasokhov
AKA. A. Kostin
A. A. Kostin
VAV. L. Astashov
V. L. Astashov
ATA. V. Turiev
A. V. Turiev
AUA. D. Uskov
A. D. Uskov
Purpose of the study. To evaluate the effect of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) on the quality of life of patients during standard combined treatment of newly diagnosed ovarian cancer.Patients and methods. A combination of surgical cytoreduction with a simultaneous session of intra‑abdominal aerosol chemotherapy under pressure and subsequent systemic chemotherapy within the framework of a single hospitalization was used. The study included 164 patients (79 in the main group, 85 in the control group). All patients were operated on at the first stage, all underwent systemic cytostatic therapy according to the TS scheme (6 courses with an interval of 21 days). In the main group, 3 PIPEC sessions were added to standard treatment: the first one simultaneously with cytoreductive surgery, followed by 2 more PIPAC sessions with an interval of 42 days. To assess the quality of life, the EORTC‑QLQ – C30 questionnaire was used, which the patients filled out 4 times: before the cytoreductive stage, and then after completing the first, third and fifth courses of systemic polychemotherapy (PCT).Results. Before the start of treatment in the control group, the average general condition was 1.6 ± 1.1 points, then 1.32 ± 1.0 points, then 0.96 ± 0.97 and 0.78 ± 0.87 points at the end of the 6th course of systemic PCT. A similar situation has developed in the main group. The average baseline value before treatment was 1.7 ± 1.1 points, with the second questionnaire – 1.3 ± 1.1 points, with the third questionnaire – 0.66 ± 0.83, and 0.43 ± 0.75 points with the fourth questionnaire. In the control group, the average assessment of the quality of life before treatment was 55.0 ± 11.0 points, and then sequentially with the following three surveys 50,8 ± 7,5, 47 ± 8, 45,6 ± 8,1 points, which indicates an improvement in the quality of life against the background of ongoing treatment. In the main group, the basic level of assessment of the quality of life was 53.8 ± 11.3 points. Subsequently, an improvement in the indicators was also revealed: 49.6 ± 7.5 points, 44.2 ± 5.3 points and 42.1 ± 5.4 points, respectively. The homogeneity of the distribution in the groups was established by means of an accurate two–way Wilcoxon–Mann‑Whitney rank sum criterion, the actual significance level was p = 0.498. A two‑factor model of nonparametric analysis of variance (ANOVA) was used to analyze the data obtained. To identify a significant difference between the indicators at different stages of the study, the Page rank criterion for an ordered alternative and an algorithm based on the Friedman rank sum test were used. As a result, it was shown that the revealed positive dynamics of indicators within the groups over the entire study period is statistically significant (p < 0.0001).Conclusion. The results of the study showed that PIPAC not only does not reduce the quality of life and does not worsen the well‑being of patients, but also improves these indicators by the time of completion of combined treatment (after the 6th course of systemic PCT): in the main group, the overall ECOG condition at this stage was estimated at 0.43 ± 0.75 points, in the control group – 0.78 ± 0.87 points. The survey of patients using EORTC‑QLQ – C30 at this stage showed that in the main group the indicator was 42.1 ± 5.4 points versus 45.6 ± 8.1 points in the control group of the study.

23 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
ADA.S. Dzasokhov
A.S. Dzasokhov
AKA.A. Kostin
A.A. Kostin
VAV.L. Astashov
V.L. Astashov
ATA.V. Turiev
A.V. Turiev
AKA.V. Kuchuk
A.V. Kuchuk
Objective. Assessment of the safety profile and adverse events in women with newly diagnosed ovarian cancer and peritoneal carcinomatosis using two-component chemotherapy, including pressurized intraperitoneal aerosol chemotherapy, after surgical cytoreduction. Material and methods. The study included 164 patients with morphologically verified peritoneal carcinomatosis. All the women were divided into two groups. The distribution of patients into groups was carried out during cytoreductive surgery using a digital online randomizer. The first group of the study (the main one) included patients (n=79) who underwent intra-abdominal aerosol chemotherapy under pressure immediately after the completion of the cytoreductive stage of the operation within one surgical intervention and after 1.5 months, as well as courses of polychemotherapy. The second group (n=85) included women who underwent surgical treatment and polychemotherapy. In both observation groups, all adverse events were recorded according to the criteria of the Common Terminology Criteria for Adverse Events (CTCAE). Results. In the first group of patients during the analyzed time period, a total of 237 courses of PCT and 151 PIPAC sessions were conducted, while we registered 170 (71.7%) cases of adverse events. In the second group, 255 courses of systemic PCT were conducted at the end of the observation. At the same time, 184 (72.1%) episodes of the development of adverse events of a toxicological profile were registered. In none of the women from the first and second observation groups did we record the presence of adverse events of the 4th degree of severity. There were no statistically significant differences between the comparison groups regarding the occurrence of adverse events. Conclusion. At the intermediate stage of a prospective controlled randomized trial, it was possible to establish a favorable safety profile of intraperitoneal aerosol chemotherapy under pressure, used in addition to the standard combined treatment of newly diagnosed ovarian cancer with peritoneal carcinomatosis.

7 June 2026 in South Russian Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasokhov
A. S. Dzasokhov
ESE. Yu. Stolbova
E. Yu. Stolbova
ATA. V. Turiev
A. V. Turiev
VAV. L. Astashov
V. L. Astashov
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
KIK. B. Ischenko
K. B. Ischenko
Peritoneal carcinomatosis in advanced ovarian cancer is an unfavorable prognostic factor and limits the efficacy of systemic chemotherapy. This provides a rationale for the use of locoregional treatment modalities, including pressurized intraperitoneal aerosol chemotherapy (PIPAC). Of particular interest is the safety of a bidirectional strategy (systemic chemotherapy + PIPAC) in patients requiring multivisceral resection. We present a clinical case of a patient with advanced ovarian cancer and peritoneal carcinomatosis. Induction bidirectional chemotherapy was administered, consisting of paclitaxel/carboplatin (6 cycles) combined with PIPAC using cisplatin 30 mg/m² (50 mg), 30-minute exposure, 3 sessions, followed by multivisceral cytoreductive surgery. Efficacy was assessed based on tumor marker dynamics, peritoneal cancer index (PCI), and morphological response (TRG), while safety was evaluated according to perioperative complications and the feasibility of continuing PIPAC after surgery. At initial laparoscopy in April 2025, peritoneal carcinomatosis was detected (PCI 26); the first PIPAC session was performed, followed by systemic chemotherapy. After the second cycle, a partial response was documented. In June 2025, multivisceral cytoreductive surgery was performed, including anterior resection of the rectum with sigmoid stoma formation. Systemic therapy was resumed early and completed up to 6 cycles. By 20.08.2025, tumor markers had decreased: CA-125 to 47 U/mL, CA 19–9 to 13.7 U/mL, and HE-4 to 120 U/mL. Before PIPAC-2 (September 2025), no macroscopic carcinomato sis was detected (PCI 0); no tumor cells were found in peritoneal biopsy specimens, corresponding to TRG 1. At PIPAC-3 (November 2025), PCI remained 0, and repeat biopsies also corresponded to TRG 1. Induction bidirectional chemotherapy including PIPAC in a patient with advanced ovarian cancer and peritoneal carcinomatosis demonstrated clinical feasibility, safety and marked antitumor efficacy even after multivisceral cytoreduction.